A rabbit model for Staphylococcus aureus osteomyelitis was used to compare treatment with clindamycin and cefazolin. Cefazolin (5 mg/kg), cefazolin (15 mg/kg), and clindamycin (70 mg/kg) were injected subcutaneously every 6 h for 28 days. After treatment, S. aureus was found in bone cultures from 22 of 23 control rabbits, 12 of 22 rabbits treated with cefazolin (5 mg/kg), 12 of 23 rabbits treated with cefazolin (15 mg/kg), and 2 of 20 rabbits treated with clindamycin. Drug concentrations in serum, uninfected bone, and infected bone were measured 30 mim after cefazolin or clindamycin was injected into a group of rabbits which had been infected for 3 to 4 weeks. Clindamycin gave the highest concentration in infected and uninfected bone. The results of the study showed that clindamycin was superior to cefazolin in the eradication of S. aureus from infected bone in an experimental model.
MATERIALS AND METHODS
Induction of osteomyelitis infection. The original strain of S. aureus was obtained from Carl Norden, Montefiore Hospital, Pittsburgh, Pa. The organism was passed through a mouse to maintain its virulence and stored in defibrinated sheep blood at -70°C. Antibiotic tube dilution susceptibilities (4) of this S. aureus (10W CFU) were determined in cation-supplemented Mueller-Hinton broth.
New Zealand White rabbits weighing approximately 2 kg were used in this study. An 18-gauge needle was inserted percutaneously through the lateral aspect of the left tibial metaphysis into the intramedullary cavity. Sequential injections (15) were made of 0.1 ml of 5% sodium morrhuate (Eli Lilly & Co., Indianapolis, Ind.), 0.1 ml of S. aureus (7 x 106 CFU), and 0.1 ml of sterile saline. The needle was removed, and the animal was returned to the cage.
Therapeutic trials. The animals were randomized into four groups at the time the infection was induced (day zero), and treatment was begun 14 days later. At least two infected * Corresponding author. untreated controls (group 1) were included in each treatment series. Group 2 received cefazolin (5 mg/kg) every 6 h, group 3 received cefazolin (15 mg/kg) every 6 h, and group 4 received clindamycin (70 mg/kg) every 6 h. The antibacterial agents were administered from day 14 through day 42 (28 days total). The injections were given subcutaneously into the back of the neck. Following completion of the treatment regimen, the animals were observed for 2 weeks before sacrifice. Antibiotic doses were selected which achieved concentrations in serum comparable to those found in humans given optimal parenteral therapy with these antibiotics.
Radiographs of both tibias were taken at antibiotic initiation (day 14), at antibiotic termination (day 42), and before sacrifice (day 56). Severity of the infection by roentgenographic appearance was graded by a system previously reported (15) . The animals were weighed before infection and once weekly until they died or were sacrificed.
Bone cultures. At the conclusion of the study, animals were sacrificed by an intracardiac injection of sodium pentobarbital. The bones were cultured by the method previously reported (15) . The proximal and distal ends of the tibia were swabbed and streaked to check for any bacterial growth. Sterile tryptic soy broth (1 ml) was flushed through the marrow cavity, and then 0.5 ml of the tryptic soy broth was recovered and cultured quantitatively by serial dilution techniques. MICs and MBCs (4) were determined for the recovered S. aureus from the treatment failure rabbits.
Hematologic measurements. The sedimentation rate (modified Wintrobe test), hematocrit, and blood leukocyte count were measured before infection, at antibiotic initiation, at antibiotic termination, and prior to sacrifice.
Antibiotic serum kinetics and simultaneous measurements of levels in serum and bone. A group of uninfected animals and a group of animals that had been infected 3 to 4 weeks previously were given a single subcutaneous injection of Antibiotic assays of serum and bone. Cefazolin concentrations in serum and bone were measured by using Bacillus subtilis as the test organism. A 0.1-ml B. subtilis spore suspension (Difco Laboratories, Detroit, Mich.) was added per 100 ml of antibiotic medium 1 (Difco). Five milliliters of the seeded agar was pipetted evenly onto petri plates (100 by 15 mm). Serum standards of cefazolin were prepared with known concentrations of the antibiotic (stored at 1,000 ,ug/ml at -20°C) diluted in 100% normal rabbit serum on the day of the assay. Standards ranged from 0.20 to 100 ,ug/ml and were diluted by serial twofold decrements. Serum standard or serum samples (20 RlI) were placed on each of four sterile blank concentration disks (0.25 in. [ca. 0.6 cm]; Difco), plated on the seeded agar plate, and incubated at 37°C overnight. The diameters of the zones of inhibition of growth ofB. subtilis were measured for both samples and standards. Unknown concentrations were determined from standard curves. Blood was drawn from each rabbit prior to the administration of cefazolin, and the serum was tested for inhibitory substances to the test organism. If inhibition was detected, the animal was not used for the study.
An anaerobic disk-diffusion assay described by Sabath and Toftegaard (24) was used for clindamycin assays of serum and bone. Clostridium perfringens (UUMC 9758) stock was frozen (-70°C) in defibrinated sheep blood, subcultured into prereduced cooked meat glucose (Austin Biologicals, Austin, Tex.) supplemented with 2 to 3 drops of fresh defibrinated sheep blood, sealed, and grown overnight at 37°C. Seeded blood agar plates were prepared by adding 0.15 ml of the C. perfringens overnight culture to 1.4 ml of sterile defibrinated sheep blood in 15 ml of liquefied brain heart infusion agar. Fifteen milliliters of this seeded blood agar was pipetted and distributed evenly onto each sterile petri plate (15 by 150 mm). Serum standards of clindamycin were prepared with known concentrations of the antibiotic and then diluted in 100% normal rabbit serum on the day of the assay. Values ranged from 1 to 20 ,ug/ml. Clindamycin was stored at 1,000 p.g/ml at -20°C. Twenty milliliters of serum standard or sample were placed on each of four sterile blank concentration disks (0.25 in. [ca. 0.6 cm]; Difco), plated on the seeded agar plate, and incubated in an anaerobic incubator for approximately 3 to 4 h, until zones of inhibition of growth were easily discernible. Concentrations were measured as stated previously. Blood was drawn from each rabbit prior to the administration of clindamycin, and the serum was tested for inhibitory substances to C. perfringens. If inhibition was detected, the animal was not used in the study.
Infected and uninfected bone was prepared for assay by grinding the entire tibia in an IKA Werk Bone mill (Janke & Kunkel, Inc., Staufen in Breisgan, Federal Republic of Germany). The drug was eluted in a mixture of equal parts of normal rabbit serum and 0.1 M phosphate buffer (pH 7.5). One milliliter of the buffer-serum solution was used per 0.5 g of bone. Standard solutions of the drugs were prepared by adding normal uninfected bone to buffer-serum solution containing known amounts of drug. The lower limit of detection of the assay was 0.05 ,ug/ml for cefazolin and 0.1 ,ug/ml for clindamycin.
Statistics. The data were analyzed either by the chi-square technique or by the unpaired Student t test.
RESULTS
Of the 97 rabbits that were infected for the study (Table 1) , 9 (9.3%) died before treatment, which began on day 14, and were not included in the data analysis.
Bone cultures. Cultures from 22 of 23 (95.7%) untreated infected (control) rabbits yielded S. aureus. Cultures were positive for S. aureus in 12 of 22 (54.6%) cefazolin (5 mg)-treated rabbits, 12 of 23 (52.2%) cefazolin (15 mg/ kg)-treated rabbits, and 2 of 20 (10%) rabbits treated with clindamycin. The difference between each drug treatment group and the control group was significant at P < 0.005. The differences between the clindamycin group and the cefazolin groups were also significant at P < 0.01. No significant difference was found between the groups treated with 5 mg and 15 mg of cefazolin per kg. The MICs and MBCs of cefazolin for this S. aureus strain were both 0.39 pug/ml. The MIC of clindamycin for this S. aureus strain was 0.1 pug/ml, and the MBC was 0.20 pug/ml. Rabbits in which treatment failed all demonstrated MICs and MBCs of both drugs for S. aureus isolates which were within 2 dilutions of the corresponding values for the S. aureus isolates used to infect the rabbits. The number of viable bacteria (mean plus or minus the log1o standard error of the mean [SEMI) found in the flushing of the left tibia for the infected control rabbits (4.23 ± 0.32) was significantly higher than the values for the cefazolin (5 mg/kg)-treated animals (2.10 0.33), for the cefazolin (15 mg/kg)-treated animals (1.77 0.29), and for the clindamycin-treated group (1.22 + 0.15) (P < 0.001). In addition, the mean number of bacteria found in the left tibial flushing for clindamycin was significantly lower than for either of the cefazolin treatment groups (P < 0.05). There were no significant differences between the cefazolin treatment groups.
Mortality. Differences in mortality rates were not significant for any of treatment groups compared: cefazolin (5 mg/kg), cefazolin (15 mg/kg), clindamycin (70 mg/kg), or the control groups. Four of the seven rabbits which died in the clindamycin group had a diarrheal illness before death. Cultures from these animals were negative for Clostridium difficile.
Changes in weight. The mean weight for all four groups of rabbits decreased from induction of infection (day zero) to the beginning of therapy (week 2) but subsequently increased to the conclusion of the study. Of the rabbits treated, the ones receiving clindamycin gained the least weight (0.59 0.11 kg) during the study (P < 0.005).
Radiographic severity of infection. The roentgenographic severity scores of the infected bones measured before therapy (week 2) were similar for the control and all three treatment groups. These severity scores showed a significant improvement (P < 0.05) from week 2 to week 8 of the study in those rabbits treated with clindamycin. There was no roentgenographic improvement in either of the cefazolin treatment groups. The infected control rabbits had comparable severity scores throughout the study. The majority of the rabbits had sequestra.
Concentrations of antibiotic in serum and bone. Concentrations of cefazolin (5 mg/kg), cefazolin (15 mg/kg), and clindamycin (70 mg/kg) in the sera of infected and uninfected rabbits after single subcutaneous injections of the respective drugs are shown in Table 2 . Table 3 compares simultaneous concentrations in serum, noninfected bone, and infected bone of 5 and 15 mg of cefazolin per kg and 70 mg of clindamycin per kg at 30 min after a single subcutaneous injection of antibiotic. Clindamycin gave the highest bone levels in both uninfected and infected bone (P < 0.005). The mean concentrations in infected bone were significantly higher for the three drugs than the respective values for uninfected bone (P < 0.05).
DISCUSSION
In the experiments reported here, cefazolin and clindamycin were effective in eradicating S. aureus from experimental osteomyelitis. Posttreatment, 45% of cefazolin (5 mg/kg)-treated animals and 47% of cefazolin (15 mg/kg)-treated animals had negative tibial cultures for S. aureus. Treatment with clindamycin was most effective; 90% of the treated rabbits had negative S. aureus tibial cultures. S. aureus isolated from the rabbits with positive tibial cultures showed no evidence of resistance to the treatment antibiotics.
The quantitative counts of the bone washing revealed approximately 104 CFU of S. aureus per ml in the control animals. These counts probably underestimate the true tibial bacterial load since there are sequestered or trapped organisms present in infected bone. However, in the treatment animals, the decreased quantitative counts probably reflect effective therapy. The lowest S. aureus mean bone washing count was seen with clindamycin therapy.
Radiographic severity of infection was used as an objective measure of osteomyelitis. Both controls and all treatment groups began the treatment phase with nearly identical radiographic severity scores. This demonstrates that all groups had a similar acuity of osteomyelitis at the initiation of the therapy phase. Radiographic improvement from the initiation of therapy to the end of the study was found only in the clindamycin treatment group.
Clindamycin and cefazolin concentrations in rabbit serum were comparable to those found in humans who are given (2) . S. aureus possesses unique characteristics which are relevant to the production and the chronicity of osteomyelitis. In osteomyelitic bone, S. aureus has been found to elaborate large amounts of fibrous exopolysaccharide material (18) . As the bone infection progresses, the organisms are enveloped in a matrix of these hydrated, predominately anionic components, termed glycocalyx. Glycocalyx modifies the environment of the adherent organisms by concentrating nutrients and by protecting them from surfactants (7), antibiotics (19) , and phagocytic cells (26) . Glycocalyx protection may partially account for the recalcitrance of staphylococcal osteomyelitis to treatment. Mayberry-Carson and co-workers (16, 17) have demonstrated that clindamycin therapy in experimental S. aureus osteomyelitis appeared to reduce glycocalyx formation. Moreover, it has been shown that this glycocalyx reduction precedes bacterial killing (17) . Glycocalyx reduction facilitates antibiotic and phagocytic cell access to the S. aureus which leads to increased killing of this organism. In this model, inhibition of glycocalyx could be one of the mechanisms responsible for the excellent results with clindamycin.
Despite its wide use, cefazolin is not the drug of choice for the treatment of S. aureus osteomyelitis. In patients who are not allergic to penicillin, semisynthetic penicillins are the antibiotics of choice. In a previous study, using the same rabbit model and strain of S. aureus (14) , nafcillin sterilized 12 of 20 tibias (60%). Thus, in the same model nafcillin was similar to cefazolin in the treatment of S. aureus osteomyelitis.
When multiple parameters were used, clindamycin was found to be more effective than cefazolin for the treatment of experimental S. aureus osteomyelitis. Clindamycin treatment results demonstrate that this agent is best for monotherapy in the S. aureus osteomyelitis rabbit model (13, 15, 21 
